Data as of Nov 4, 2026.
BIOY vs NDIV: Dividend Yield & Total Return
BIOY and NDIV both write options for income.
askIQ about this page
askIQ about BIOY and NDIV
Net assets on Nov 3, 2026: $1.5m for GraniteShares YieldBOOST Biotech ETF and $34m for Amplify Energy & Natural Resources Covered Call ETF.
13.6 pts behind XBI
BIOY since launch: paid 26.1%, price −21.9%, total +5.4%, XBI +19.0%, −13.6 pts. Data to Nov 4, 2026.
XBI
+19.0%
BIOY
+5.4%
26.1% cash
13.6 pts behind XBI
Total return, distributions reinvested
13.6 pts behind XBI
BIOY since launch: paid 26.1%, price −21.9%, total +5.4%, XBI +19.0%, −13.6 pts. Data to Nov 4, 2026.
XBI
+19.0%
BIOY
+5.4%
13.6 pts behind XBI
26.1% of it arrived as cash. Total return, distributions reinvested. BIOY since launch: paid 26.1%, price −21.9%, total +5.4%, XBI +19.0%, −13.6 pts. Data to Nov 4, 2026.
Data to Nov 4, 2026.Not measured
NDIV over 1 year: paid 12.3%, price +28.1%, total +41.1%, not measured against a benchmark. Data to Nov 4, 2026.
NDIV
+41.1%
12.3% as cash
Total return, distributions reinvested
Not measured
NDIV over 1 year: paid 12.3%, price +28.1%, total +41.1%, not measured against a benchmark. Data to Nov 4, 2026.
NDIV
+41.1%
12.3% of it arrived as cash. Both charts share one scale, with zero at the line. NDIV over 1 year: paid 12.3%, price +28.1%, total +41.1%, not measured against a benchmark. Data to Nov 4, 2026.
Data to Nov 4, 2026.Pair scorecard
NDIV costs 0.59 points a year less; NDIV is far larger, $34m against $1.5m.
Points (pts) are percentage points.
| Measure | BIOY | NDIV |
|---|---|---|
| Paid and earned | ||
| Total return, 1 year | not published | +41.1% |
| Price change | fell 21.9% (since May 5, 2026) | rose 28.1% (1 year) |
| Return of capital, issuer estimate | 96% of the Sep 22, 2026 payment | 96% of the Oct 30, 2026 payment |
| Against its benchmark | ||
| Benchmark | Biotech, measured through XBI | its own stocks |
| Cost and size | ||
| Expense ratio | 1.18% | 0.59% |
| Net assets, as of Nov 3, 2026 | $1.5m | $34m |
| Holdings | ||
| Holdings in common | 0% | |
What they share
By the books each fund has filed, BIOY and NDIV hold 0% of their money in the same securities at the same weight. Holdings dated Jun 30, 2026 and Nov 4, 2026.
half
0% in common
Only in one fund ↓
Side by side
As of Nov 4, 2026. Source: ETFIQ. Cash paid: distributions over the window, as a share of the starting price. Payout rate: the latest payment, annualized, over today’s price.
Window by window
| Total return | Cash paid | Against the benchmark | ||||
|---|---|---|---|---|---|---|
| Window | BIOY | NDIV | BIOY | NDIV | BIOY | NDIV |
| 3 months | +6.9% | +5.0% | 14.5% | 3.0% | +2.9 pts | not measured |
| 6 months | +4.4% | +0.8% | 25.9% | 5.5% | −11.3 pts | not measured |
| 1 year | – | +41.1% | – | 12.3% | – | not measured |
| 3 years | – | +54.0% | – | 24.0% | – | not measured |
| Since launchNot the same days: BIOY May 2026 · NDIV Aug 2022 | +5.4% | +74.7% | 26.1% | 33.2% | −13.7 pts | not measured |
– means no data for this window. Open this comparison in the app →
BIOY
Over the period from its first trade on May 5, 2026 to Nov 4, 2026, BIOY paid 26.1% of its starting value in cash distributions while its price fell 21.9%. With every distribution reinvested, the fund returned +5.4%. Biotech (XBI) returned +19.0% over the same days, so a holder was behind by 13.6 pts. At its price on Nov 4, 2026 the latest distribution annualizes to 60.7%, paid weekly. GraniteShares estimates that 96% of the distribution paid Sep 22, 2026 was a return of capital (its 19a-1 notice). That is a tax label, not a measure of erosion.
No 1-year comparison: a quarter's holdings filing is missing from the year.
Over the year to Nov 4, 2026, NDIV paid 12.3% of its starting value in cash distributions while its price rose 28.1%. With every distribution reinvested, the fund returned +41.1%. At its price on Nov 4, 2026 the latest distribution annualizes to 11.5%, paid monthly. Amplify estimates that 96% of the distribution paid Oct 30, 2026 was a return of capital (its 19a-1 notice).
Questions people ask
Links are sources, not endorsements. A comparison is not a recommendation.
How this is computed
Overlap adds up the smaller of the two weights for each security both funds hold.
Every number is an ETFIQ calculation with distributions reinvested.
Cite this pageCitation, APA and Markdown
ETFIQ, BIOY against NDIV, data as of Nov 4, 2026. https://etfiq.com/compare/income/bioy-vs-ndiv
ETFIQ. (Nov 4, 2026). BIOY against NDIV. Retrieved from https://etfiq.com/compare/income/bioy-vs-ndiv
[BIOY against NDIV (ETFIQ, Nov 4, 2026)](https://etfiq.com/compare/income/bioy-vs-ndiv)
Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.